  |
 | Up a level |
Gafanov, R. and Powles, T.B. and Bedke, J. and Stus, V. and Wadde, T.S. and Nosov, D. and Pouliot, F. and Soulières, D. and Melichar, B. and Azevedo, S. and McDermott, R.S. and Vynnychenko, I. and Borchiellini, D. and Markus, M. and Bondarenko, I. and Lin, J. and Burgents, J. and Molife, L. R. and Rini (2021) Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study. Annals of Oncology, 32 (5). p. 694. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
Rini, B.I. and Plimack, E.R. and Stus, V. and Gafanov, R. and Hawkins, R. and Nosov, D. and Pouliot, F. and Alekseev, B. and Soulières, D. and Melichar, B. and Vynnychenko, I. and Kryzhanivska, A. and Bondarenko, I. and Azevedo, S.J. and Borchiellini, D. and Szczylik, C. and Markus, M. and McDermott, R.S. and Bedke, J. and Tartas, S. and Chang, Y.-H. and Tamada, S. and Shou, Q. and Perini, R.F. and Chen, M. and Atkins, M.B. and Powles, T. (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine = N Engl J Med, 380. pp. 1116-1127. ISSN 0028-4793 (print); 1533-4406 (online)
